capecitabine has been researched along with Intestinal Neoplasms in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Badesha, J; Boutin, M; Farnell, D; Gill, S; Loree, JM; Mathews, A; Paul, A; Safro, M; Schaeffer, D; Stuart, HC | 1 |
| Bernards, N; Creemers, GJ; de Hingh, IHJT; Legué, LM; Lemmens, VEPP; van Erning, FN | 1 |
| Claringbold, PG; Grover, P; Kesavan, M; Lam, WS; Turner, JH | 1 |
| Ames, MM; Foster, NR; Goetz, MP; Hobday, TJ; Horvath, LE; Jatoi, A; Mahoney, MR; McWilliams, RR; Meyers, JP; Murray, JA; Schneider, DJ; Smyrk, TC | 1 |
| Akashi, K; Arita, S; Ariyama, H; Baba, E; Esaki, T; Inadomi, K; Kusaba, H; Makiyama, A; Makiyama, C; Mitsugi, K; Shibata, Y; Shinohara, Y; Shirakawa, T; Takayoshi, K; Tsuchihashi, K; Uchino, K; Uenomachi, M | 1 |
| Dureja, S; Gupta, SK; Kumar, S; Kumari, J; Malasani, V; Pant, V; Sen, I; Thakral, P; Un, P | 1 |
| Costa, FP; Gumz, B; Pasche, B | 1 |
| Claringbold, PG; Kesavan, M; Turner, JH | 1 |
| Abbruzzese, JL; Adinin, R; Eng, C; Kopetz, S; Lin, E; Morris, JS; Overman, MJ; Varadhachary, GR; Wolff, RA | 1 |
| Eskola, M; Ilveskoski, E; Nikus, K; Tanner, M | 1 |
| Orphanos, GS; Picolos, MK; Stavrou, NG | 1 |
1 review(s) available for capecitabine and Intestinal Neoplasms
| Article | Year |
|---|---|
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Proliferation; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Intestinal Neoplasms; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Prognosis; Stomach Neoplasms; Streptozocin; Temozolomide | 2012 |
4 trial(s) available for capecitabine and Intestinal Neoplasms
| Article | Year |
|---|---|
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Temozolomide; Treatment Outcome | 2021 |
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Care Facilities; Capecitabine; Databases, Factual; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Glucuronosyltransferase; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis | 2017 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Neutrophils; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stomach Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2014 |
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Common Bile Duct Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Time Factors; Treatment Outcome | 2009 |
6 other study(ies) available for capecitabine and Intestinal Neoplasms
| Article | Year |
|---|---|
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Female; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Netherlands; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Quinazolines; Registries; Retrospective Studies; Survival Rate | 2019 |
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Japan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxonic Acid; Retrospective Studies; Survival Rate; Tegafur | 2017 |
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabine; Case-Control Studies; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Intestinal Neoplasms; Liver; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Spleen; Stomach Neoplasms; Temozolomide; Tissue Distribution | 2018 |
[Coronary artery disease attack caused by cytotoxic chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chest Pain; Coronary Vasospasm; Deoxycytidine; Female; Fluorouracil; Humans; Intestinal Neoplasms; Male; Middle Aged | 2009 |
Hypertriglyceridemia: An underdiagnosed side effect of Capecitabine chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Bezafibrate; Capecitabine; Cecum; Deoxycytidine; Fluorouracil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Intestinal Neoplasms; Male; Middle Aged; Neoplasm Staging | 2010 |